Eradivir Secures $10.25M for Influenza Study

Eradivir Completes Series A Funding

Eradivir, a preclinical biotech company specializing in antiviral therapeutics, recently completed a $10.25 million Series A funding round. These funds will drive the Phase 2a challenge study of their innovative influenza treatment, EV25. The company's CEO, Martin Low, emphasizes the superior performance of EV25 in preclinical trials, stating that the therapeutic has consistently outperformed current influenza treatments.